Substituted 2-anilinopyrimidine derivatives as EGFR modulators

US10590111B2 · kind B2 · utility

Assignee

• BETA PHARMA, INC. · US

Inventors

• Jirong Peng · Mequon, US
• Michael John Costanzo · Bonney Lake, US
• Michael N. Greco · Lansdale, US
• Michael Alan Green · Easton, US
• Victoria Lynn Wilde · Montclair, US
• Don Zhang · Princeton, US

Key dates

• Filing date: Dec 11, 2015
• Grant date: Mar 17, 2020
• Expiry date: Dec 11, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This application discloses novel substituted 2-anilinopyrimidine derivatives, and pharmaceutically acceptable salts, solvates, prodrugs, and compositions thereof, which are useful for the treatment or prevention of diseases or medical conditions mediated by epidermal growth factor receptors (EGFRs), including but not limited to a variety of cancers.